Phase I trial of SPX 106t, a fixed-dose combination of D-tagatose and SPX 106.

Trial Profile

Phase I trial of SPX 106t, a fixed-dose combination of D-tagatose and SPX 106.

Planning
Phase of Trial: Phase I

Latest Information Update: 13 Aug 2012

At a glance

  • Drugs D-tagatose/SPX 106 (Primary)
  • Indications Dyslipidaemias; Hypertriglyceridaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Aug 2012 Planned initiation date changed from 1 Jun 2012 to 1 Dec 2012, as reported in a Spherix media release.
    • 11 Jan 2012 Planned initiation date changed from 1 Mar 2012 to 1 Jun 2012, according to a Spherix Incorporated media release.
    • 09 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top